All eyes are on those on the front lines seeking to develop and produce new drugs. There’s unprecedented pressure to offer both immediate treatments for those affected and long-term biotherapies and vaccines to prevent future epidemics.
Advanced therapy medicinal product (ATMP) companies are ushering in a new frontier of medicine and technologies poised to revolutionize human health, but are ATMP facilities keeping up? The industry is advancing at such a rapid pace that these companies are faced with vast new complexities when developing and manufacturing their products.
Too often, the term “closed process” is thrown around without an understanding of the salient issues. Pharmaceutical process closure can certainly provide many benefits, but there are various impacts and requirements depending on the ultimate goal and the specific process you are trying to close.